|
WO2007028394A2
|
|
Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
|
|
EP1874339A1
|
|
Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
|
|
US2008300180A1
|
|
Growth Hormone Secretagogue Receptor 1A Ligands
|
|
WO2006045319A2
|
|
Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
|
|
WO2006045313A2
|
|
Uses of secretagogues for treatment of organ transplant patients
|
|
WO2006045314A2
|
|
Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
|
|
WO2005097174A2
|
|
Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
|
|
WO2005097173A2
|
|
Use of ghrelin for the treatment of hyperthyroidism
|
|
WO2005097831A2
|
|
Uses of isolated binding members capable of binding specifically to secretagogues
|
|
WO2005014032A2
|
|
Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
|
|
US2007037751A1
|
|
Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
|
|
CN1863550A
|
|
Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
|
|
KR20050057650A
|
|
Use of ghrelin for treating malnutrition in gastrectomized individuals
|
|
NZ506163A
|
|
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
